Hyperlipidemias Clinical Trial
Official title:
A Randomized, Single-center, Open, Parallel, Phase 4 Study to Compare the Efficacy and Safety of Rosuvastatin/Ezetimibe Combination Therapy Versus Rosuvastatin Monotherapy in Korean Patients With Left Ventricular Diastolic Dysfunction and Hyperlipidemia
preserved left ventricular ejection fraction (LVEF ≥ 50%) and are accompanied by dyslipidemia (LDL ≥ 100 mg / dl) will be enrolled. Only patients who do not meet the exclusion criteria should be enrolled in the study. Once the patient is selected, the patient is informed of the study and receives the consent form. Patients who are eligible for all of the criteria and who do not qualify as exclusion criteria should be enrolled in the study and randomly assigned in a 1: 1 dose of rosuvastatin/ezetimibe 10/10mg once daily or rosuvastatin 20 mg once daily. Patients who previously used statins have a wash-out period of 4 weeks or more. Patients will visit outpatient clinic at 12 weeks and 24 weeks after initiation of treatment. Physical examination, blood test, and 6 minute working test will be performed. For fasting blood tests, patients visit on an empty stomach. Drug adverse events and changes in vital signs or body weight will be checked. After 48 weeks of treatment, the patients will visit outpatient clinic for efficacy evaluation; physical examination, blood test, transthoracic echocardiography, cardiopulmonary exercise test, central blood pressure, and pulse wave velocity. Drug adverse events and medication compliance will be checked. The primary endpoint is change of low-density lipoprotein cholesterol and secondary endpoint is improvement of diastolic dysfunction, VAC index, peak VO2, distance of 6 minute working test, and clinical outcomes including death, readmission rate.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03793985 -
Compare the Pharmacokinetics and Safety of CKD-391 With Co-administration of D086 and D337
|
Phase 1 | |
| Recruiting |
NCT03947866 -
Ezetimibe-Rosuvastatin Evaluation Study
|
||
| Withdrawn |
NCT04922424 -
Mechanisms and Interventions to Address Cardiovascular Risk of Gender-affirming Hormone Therapy in Trans Men
|
Phase 1 | |
| Completed |
NCT04516291 -
A Dose-Ranging Study With Vupanorsen (TRANSLATE-TIMI 70)
|
Phase 2 | |
| Completed |
NCT04701775 -
Effect of Different Probiotic Strains in Hypercholesterolemic Patients
|
N/A | |
| Completed |
NCT03632668 -
Evaluating the Pharmacokinetic Interaction Between AD-2071 and AD-2072
|
Phase 1 | |
| Completed |
NCT03534661 -
L-NMMA on GLP-2 Mediated Intestinal Lipoprotein Release
|
Phase 2/Phase 3 | |
| Completed |
NCT03422666 -
Plasma Lipoprotein Response to Glucagon-like Peptide-2
|
Phase 2/Phase 3 | |
| Completed |
NCT00536796 -
Percentage of Secondary Prevention Patients Treated to Their LDL-C Targets
|
N/A | |
| Completed |
NCT03643705 -
A Nurse-led Intervention to Extend the HIV Treatment Cascade for Cardiovascular Disease Prevention
|
N/A | |
| Recruiting |
NCT04560296 -
Community-based E-Health Program for Older Adults Living With Chronic Diseases
|
N/A | |
| Terminated |
NCT04073134 -
The CHORAL Flow Study
|
Phase 4 | |
| Recruiting |
NCT05103254 -
Bempedoic Acid Pregnancy Surveillance Program
|
||
| Not yet recruiting |
NCT05015348 -
Effects of Omega-3 PUFA on Lipids, Inflammatory Factors and Body Composition in Patients With Hyperlipidemia
|
N/A | |
| Active, not recruiting |
NCT05082350 -
Nutritional Intervention With Black Garlic
|
N/A | |
| Not yet recruiting |
NCT04398771 -
To Evaluate Safety and Effectiveness of RovatitanTab.
|
||
| Not yet recruiting |
NCT04064281 -
The Healthy Cantonese Diet on Cardiometabolic Syndrome
|
N/A | |
| Recruiting |
NCT06257641 -
Impact of the Mediterranean Diet on Patients With Psoriasis
|
N/A | |
| Completed |
NCT03690778 -
The PK Characteristics of the Co-administration of Metformin SR and Rosuvastatin and JLP-1310 in Healthy Male Volunteers.
|
Phase 1 | |
| Completed |
NCT04354987 -
Compare the Pharmacokinetics and Safety of CKD-391
|
Phase 1 |